

Third Announcement

Targeted Protein Degradation 5 21st - 22nd October 2026 The Fielder Centre, Hatfield

Draft
programme
available now

Registration
open



Synopsis

One of the most exciting new therapeutic modalities to emerge in the 21st century has been Targeted Protein Degradation (TPD). The targeted protein degradation (TPD) market in 2025 is estimated to be worth between approximately \$0.48 billion and \$0.65 billion, Expected to reach anywhere from \$3.5 billion to \$9.85 billion by 2034 or 2035.

This multidisciplinary meeting aims to present the latest developments in the design, biology, chemistry and ADME in TPD within the general themes of PROTACS (including non-oncology targets), Molecular Glues and non-PROTAC degraders. We aim to highlight the newest in enabling technologies such as computational techniques, Direct to Biology, HT synthesis (click, photochemistry etc) and structural biology methods.

Registration

The final deadline for registrations is 17:00 (BST) Wednesday 14 October 2026.

Standard Rate

RSC/SCI Member* £360.00

Non-Member £470.00

RSC/SCI Student ** Member* £250.00

Student** Non-Member £260.00

* Member is a paid-up member of the RSC / SCI

** Student rates apply to undergraduate and post-graduate students only

To register, [click here](#).

Confirmed Exhibitors / Sponsors



Draft Programme

Wednesday 21st October 2026

09.45 Registration Opens
10.25 Welcome and Opening Remarks
10.30 Lindsay Evans, ICR
Unhooking the Hook: Optimisation of the Aurora A Targeting PROTAC JB170 to CCT400028, an in vitro Degradation Chemical Probe
10.55 Izidor Sosič, University of Ljubljana
Condition-dependent degradation of TAK1 for the targeted therapy in autoimmune and inflammatory diseases
11.20 Karine Poullennec, BE Discovery Chemistry, UCB
Discovery of non-cytotoxic Heterobifunctional Degraders of CDK12 as potential treatment for Myotonic dystrophy (DM1)
11.45 Keynote: Krista Goodman, Larkspur Bio
Keynote Discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of Microsatellite Stable (MSS) Colorectal Carcinoma
12.25 Lunch
13.30 Martin Ambler, Amphista Therapeutics
Expanding Targeted Glue Applications for Clinical Use by Recruiting Novel E3 Ligases
13.55 Georgia Isom, University of Oxford
Molecular Glue-like Degraders of TEM β -Lactamases by Periplasmic Protease DegP
14.20 Dom Lukauskis, Ternary Therapeutics
A computational platform for the design of any molecular glue
14.45 Keynote: Lyn Jones, Dana-Farber Cancer Institute
Rewriting E3 Ligase Function: The Discovery and Development of Cereblon-Neofunctionalizing Molecular Glues
15:25 Flash Poster Presentations
15.40 Refreshment Break
16.10 Keynote (Online): Jan Kihlberg, Uppsala University
Understanding and Predicting VHL PROTAC Cell Permeability
16.50 Rebekah West, University of Cambridge
Non-ATP-Competitive PROTACs Against Aurora A Kinase
17.15 Flash Poster Presentations
17.30 Poster Presentations and networking drinks
19.00 Conference dinner

Thursday 22nd October 2026

09.00 Refreshments and exhibition
09.15 Keynote: Markus Schade, AstraZeneca
AZD9750 and the new Rule-of-oral-PROTACs
09.55 Suzanne O'Connor, University of Dundee
Tuning the open-close equilibrium of Cereblon with small molecules influences protein degradation
10.20 Keynote: Kristin Riching, Promega
Understanding How Cell Context and Intrinsic Factors Contribute to PROTAC Activity
11.00 Refreshments and exhibition
11.30 Joshua Clark, TRIMTECH Therapeutics
Leveraging the Clustering-Based Activation Mechanism of TRIM21 to Degrade Pathological Protein Aggregates
11.55 Peter Cossar, University of Dundee
Hijacking Protein Complexes: Induced Chemical Ubiquitination of 14-3-3 Complexes Enables Targeting of Non-Ligandable Proteins
12.20 Mattia Cocco, AstraZeneca
Degradation Antibody Conjugates: the good, the bad and the case studies
12.45 Lunch
13.45 John Spencer, Sussex Drug Discovery Centre, University of Sussex
Novel Linkerology in PROTAC Design
14.25 Ellie Stammers, Cancer Therapeutics, Institute of Cancer Research
D2B platform for rapid PROTAC synthesis and testing
14.50 Keynote: Alessio Ciulli, University of Dundee – BMCS Hall of Fame Winner
Charting the Evolution & Future of Targeted Protein Degradation: From Fundamental Mechanisms to Translational Impact
15.35 Closing Remarks